Zarling v. Abbott Laboratories

CourtDistrict Court, D. Minnesota
DecidedMarch 27, 2023
Docket0:21-cv-00023
StatusUnknown

This text of Zarling v. Abbott Laboratories (Zarling v. Abbott Laboratories) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Zarling v. Abbott Laboratories, (mnd 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA

JOHN ZARLING,

Plaintiff,

v. MEMORANDUM OF LAW & ORDER Civil No. 21-cv-23 (MJD/JFD)

ABBOTT LABORATORIES,

Defendant.

Mark J. Peschel, Eastlund Hutchinson Ltd., Counsel for Plaintiff

Eric M. Lloyd, Michelle L. DuCharme & Molly E. Nephew, Seyfarth Shaw, Counsel for Defendant.

This matter is before the Court on Defendant Abbott Laboratories’ (“Abbott”) Motion for Summary Judgment or, in the Alternative, Partial Summary Judgment and its Daubert Motion to Exclude Expert Testimony. (Doc. Nos. 86, 94.) Plaintiff John Zarling opposes the Motions. (Doc. Nos. 113, 120.) I. INTRODUCTION

The Court will grant Abbott’s Motion for Summary Judgment in part and deny it in part. The Court will dismiss Zarling’s claims for age, marital status, and reprisal discrimination due to a lack of sufficient evidence to create an issue for trial on these claims. To support these claims, Zarling primarily relied on a stray comment made by his supervisor during a March 2019 meeting and his

subsequent complaint to a superior about the comment. But the Court finds that the isolated nature of these events, their remoteness in time from Zarling’s termination, and the fact that a different supervisor was responsible for Zarling’s

termination, among other facts, belie any notion that Abbott terminated Zarling based on discriminatory motives.

The Court will not, however, dismiss Zarling’s breach of contract claim for severance pay as the parties’ differing allegations concerning the events leading up to Zarling’s termination and their differing interpretations of his employment

contract create issues that must be resolved at trial. The Court also will not entirely dismiss Zarling’s defamation claim against

Abbott because Zarling has presented sufficient evidence to create an issue for trial as to whether the statements in his 2019 Performance Assessment were made with “malice” in an effort to push Zarling to resign.

Finally, the Court will grant Abbott’s Daubert motion in part and deny it in part. The Court will preclude Zarling’s expert witness, Stan V. Smith, Ph.D.,

from presenting testimony on “hedonic damages” at trial for similar reasons as various other courts that have precluded Smith from providing testimony on this topic. But the Court will not preclude Smith from providing rebuttal testimony

regarding Zarling’s post-Abbott job search in response to Abbott’s vocational expert, Amy Koellner. Nor will the Court preclude Zarling’s other rebuttal expert witness, Jennifer Bey, from providing her opinion that Zarling’s post-

Abbott job search may have been impacted by age discrimination. II. BACKGROUND

A. Zarling’s Background at St. Jude/Abbott Plaintiff John Zarling began working for St. Jude Medical, S.C. (later acquired by Abbott) in 2004 as a Cardiac Rhythm Management (“CRM”) sales

representative in California’s San Francisco Bay Area. (Doc. 97-1, Ex. A at 32:7- 17, 35:8-36:1.) After a promotion in 2012, Plaintiff became a Territory Manager

and managed a team of sales representatives and technical service representatives in addition to continuing to perform his duties as a sales representative. (Id. at 38:8-19, 39:2-25, 40:8-41:23.)

B. In Early 2018, Zarling Discusses Retirement with his Supervisors In February 2018, Plaintiff’s manager was Regional Sales Manager Todd

Stewart. (Doc. 97-1, Ex. D.) Abbott’s Division Vice President, above Stewart, was Joseph Provost. (Id., Ex. A at 66:11-16; Ex. G.) On February 14, 2018, Zarling sent an email to Stewart with the subject line

“Future.” (Doc. 97-1, Ex. B.) In the email, Zarling asked for new employment contracts and pay raises for himself and some of his coworkers. (Id.) He also conveyed a plan to turn some of his sales accounts over to coworkers over the

next few years as part of an apparent retirement plan. (Id.) Zarling stated that “[b]y July 2019, active transition should be occurring . . . I may stay around after

2019 but not as an active CRM rep.” (Id.) Stewart discussed Zarling’s request with other Abbott employees, including Provost, by email. (Doc. 97-1, Ex. G.) In these emails, Stewart wrote

that Zarling was “At Will, and our intention is to have a viable succession plan in place.” (Id.) Stewart also expressed concern that Zarling would leave Abbott for

a competitor if Abbott did not honor his request for a new employment agreement. (Id.) Stewart wrote in one email to Zarling, “I will sleep better at night once the ink is dry,” apparently in reference to Zarling signing a new

employment agreement. (Doc. 97-1, Ex. F.) Zarling alleges these emails show that Abbott saw him as a flight risk, especially considering that one of his

coworkers had recently left for a competitor and took a substantial amount of business with him. (Doc. 116, Ex. 1 at 45:5-7, 302:6-303:21.) In August 2018, Zarling signed a new two-year employment agreement

with Abbott. (Doc. 97-1, Ex. A at 70:19-71:4; Ex. C at 52:19-54:15.) The contract was effective back to January 1, 2018 and expired on January 1, 2020. (Id.) Zarling continued to work as a sales representative and Territory Manager

for the remainder of 2018 and received high ratings in his 2018 Abbott Performance Assessment. (Doc. 116, Ex. 2 at 208:13-210:8; Ex. 23.) Earlier, in

2017, Abbott had awarded Zarling “Territory Manager of the Year” for the Pacific Northwest. (Id., Ex. 22.) Abbott also recognized Zarling as one of its top performing sales representatives nationwide in 2018. (Doc. 117, Ex. 7.)

C. Abbott Hires Several New Sales Employees in the Bay Area Around October 2018, Stewart recruited five new employees from a

competitor, Medtronic, to work for Abbott in the Bay Area. (Doc. 116, Ex. 1 at 58:24-59:9; Ex. 2 at 62:18-63:1; Ex. 35 ¶ 1.) Zarling alleges that Abbott had high expectations for the amount of new business these former Medtronic employees

would bring, but they ended up performing far worse than expected. (Doc. 116, Ex. 1 at 63:7-64:15; Ex. 35 ¶ 1.) Zarling claims that Stewart then set out to use him

as the “fall guy” for this failure. (Doc. 113 at 4.) In early 2019, Liane Teplitsky became the Area Vice President below

Provost. (Doc. 97-1, Ex. E at 17:15-23.) Teplitsky also became Stewart’s immediate supervisor. (Doc. 116, Ex. 2 at 30:6-10.) Zarling alleges that Teplitsky asked him to provide her with a plan to

improve the sales performance of the new team of former Medtronic employees. (Doc. 116, Ex. 1 at 183:12-184:18.) Zarling sent an email to Teplitsky and Stewart

with his proposal for the Medtronic team on March 18, 2019. (Id., Ex. 1 at 183:12- 184:18; Ex. 8.) In the email, Zarling also wrote the following about his retirement plans:

I have gone back and forth on how long I would like to work. If there was a plan in place that I felt comfortable with for the teammates, patients and physicians that allows me to leave in 2 years, with a transition starting as soon as we want, that would work for me.

(Id., Ex. 8.) Zarling also proposed that Abbott pay him a guaranteed salary through the end of 2020 and added the following proposal: “I end my run in Dec[ember] of 2020 unless some other agreement is made.” (Id.) A March 26, 2019 email from Teplitsky reiterates Zarling’s request for a guaranteed salary through the end of 2020, stating that Zarling “had planned to retire this year, but would like to stay on for an additional 1.5 years and ensure a smooth transition of his business to people he trusts.” (Doc. 116, Ex. 4.) Around

this time, Teplitsky and Stewart also prepared a PowerPoint presentation that reflected a plan to transition some of Zarling’s accounts to Nick Bosanquet, one of the new employees from Medtronic. (Doc.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Carey v. Piphus
435 U.S. 247 (Supreme Court, 1978)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Khoury v. PHILIPS MEDICAL SYSTEMS
614 F.3d 888 (Eighth Circuit, 2010)
Smith v. Ingersoll-Rand, Co.
214 F.3d 1235 (Tenth Circuit, 2000)
Rahlf v. Mo-Tech Corp., Inc.
642 F.3d 633 (Eighth Circuit, 2011)
Amini v. City of Minneapolis
643 F.3d 1068 (Eighth Circuit, 2011)
Gacek v. Owens & Minor Distribution, Inc.
666 F.3d 1142 (Eighth Circuit, 2012)
Firemen's Fund Insurance Company v. Michael Thien
8 F.3d 1307 (Eighth Circuit, 1993)
McClure v. American Family Mut. Ins. Co.
223 F.3d 845 (Eighth Circuit, 2000)
Marvin L. Fisher v. Pharmacia & Upjohn
225 F.3d 915 (Eighth Circuit, 2000)
Sherry Anderson v. Raymond Corporation
340 F.3d 520 (Eighth Circuit, 2003)
Karla Robinson v. Geico General Insurance Company
447 F.3d 1096 (Eighth Circuit, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
Zarling v. Abbott Laboratories, Counsel Stack Legal Research, https://law.counselstack.com/opinion/zarling-v-abbott-laboratories-mnd-2023.